Puma Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Puma Biotechnology
PBYI Stock  USD 6.87  0.05  0.73%   
Puma Biotechnology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Puma Biotechnology's valuation are provided below:
Gross Profit
163 M
Profit Margin
0.1744
Market Capitalization
343.7 M
Enterprise Value Revenue
1.3695
Revenue
212 M
We have found one hundred twenty available trending fundamental ratios for Puma Biotechnology, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of Puma Biotechnology recent fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 162.1 M. Enterprise Value is estimated to decrease to about 167.4 M

Puma Biotechnology Total Revenue

135.38 Million

Check Puma Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Puma Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 15 M, Other Operating Expenses of 179.8 M or Operating Income of 37.4 M, as well as many indicators such as Price To Sales Ratio of 0.61, Dividend Yield of 0.0 or PTB Ratio of 1.76. Puma financial statements analysis is a perfect complement when working with Puma Biotechnology Valuation or Volatility modules.
  
Build AI portfolio with Puma Stock
Check out the analysis of Puma Biotechnology Correlation against competitors.
For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.

Puma Biotechnology Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets168.9 M245.3 M187 M
Slightly volatile
Cash69 M79.6 M75.1 M
Pretty Stable
Cash And Short Term Investments79.2 M116.1 M87.7 M
Slightly volatile
Common Stock Total Equity4.3 K4.5 K21.3 K
Slightly volatile
Common Stock Shares Outstanding33.6 M56.5 M37.1 M
Slightly volatile
Liabilities And Stockholders Equity168.9 M245.3 M187 M
Slightly volatile
Other Stockholder Equity1.7 B1.6 B971.4 M
Slightly volatile
Total Liabilities110 M139.4 M114.7 M
Slightly volatile
Total Current Assets128.9 M169.8 M141.7 M
Slightly volatile
Common Stock4.3 K4.5 K21.3 K
Slightly volatile
Total Current Liabilities59.7 M110.5 M61.1 M
Slightly volatile
Accounts Payable11.9 M6.3 M11.3 M
Pretty Stable
Other Current Liabilities44.1 M45.7 M38.3 M
Slightly volatile
Other Liabilities7.6 M14.7 M7.7 M
Slightly volatile
Property Plant And Equipment Net8.2 M5.9 M7 M
Slightly volatile
Non Current Assets Total51.4 M75.5 M46.1 M
Slightly volatile
Non Currrent Assets Other4.3 M2.1 M4.8 M
Very volatile
Other Assets0.860.94.7 M
Slightly volatile
Non Current Liabilities Total27.4 M28.9 M52.2 M
Slightly volatile
Capital Surpluse952.6 M1.6 B928.4 M
Slightly volatile
Other Current Assets9.5 M6.9 M8.1 M
Slightly volatile
Deferred Long Term Liabilities811.7 K854.5 K1.7 M
Pretty Stable
Property Plant And Equipment Gross9.1 M14.9 M8.3 M
Slightly volatile
Property Plant Equipment1.3 M1.3 M3 M
Pretty Stable
Net Receivables26.4 M36.8 M21.6 M
Slightly volatile
Short and Long Term Debt Total85.8 M66.7 M79.4 M
Slightly volatile
Long Term Debt Total104.8 M111.7 M77.9 M
Slightly volatile
Net Invested Capital140.2 M183 M120.9 M
Slightly volatile
Short and Long Term Debt39.1 M52.1 M39.4 M
Slightly volatile
Net Working Capital48.7 M46.4 M54 M
Very volatile
Short Term Debt61.4 M58.5 M36.9 M
Pretty Stable
Capital Stock4.9 K5.8 K4.3 K
Slightly volatile
Capital Lease Obligations6 M6.3 M20.1 M
Slightly volatile
Non Current Liabilities Other1.5 M1.6 M23.9 M
Slightly volatile
Current Deferred Revenue5 M5.3 M60.4 M
Slightly volatile

Puma Biotechnology Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses179.8 M229.4 M197.1 M
Slightly volatile
Selling General Administrative67 M92.8 M70.4 M
Slightly volatile
Depreciation And Amortization13.9 M13.3 M6.1 M
Slightly volatile
Research Development84.7 M49.4 M95.1 M
Very volatile
Interest Income5.7 M5.4 M1.9 M
Slightly volatile
Reconciled Depreciation9.6 M13.3 M6.6 M
Slightly volatile
Non Recurring5.6 M6.3 M6.9 M
Slightly volatile

Puma Biotechnology Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow71.9 M82 M78.3 M
Pretty Stable
Sale Purchase Of Stock10.5 M11 M51.9 M
Slightly volatile
Depreciation13.9 M13.3 M6.1 M
Slightly volatile
Change To Netincome20.6 M21.7 M43.2 M
Very volatile
Stock Based Compensation7 M7.4 M37.1 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Days Sales Outstanding65.9858.388.0046
Slightly volatile
Average Payables268.7 K255.9 K250.9 K
Slightly volatile
Stock Based Compensation To Revenue0.03910.04111.9096
Slightly volatile
Capex To Depreciation0.00530.00569.8513
Slightly volatile
Inventory Turnover7.636.646.4655
Slightly volatile
Days Of Inventory On Hand52.9156.8683.5457
Slightly volatile
Payables Turnover11.0510.523.764
Slightly volatile
Sales General And Administrative To Revenue0.380.42.0471
Slightly volatile
Cash Per Share1.71.872.4628
Pretty Stable
Days Payables Outstanding34.1135.93.5 K
Slightly volatile
Intangibles To Total Assets0.210.220.2663
Slightly volatile
Current Ratio1.681.778.0901
Slightly volatile
Receivables Turnover7.948.285.532
Slightly volatile
Graham Number4.874.631.0797
Slightly volatile
Capex Per Share0.0010.0010.1712
Very volatile
Interest Debt Per Share1.311.61.5257
Slightly volatile
Debt To Assets0.520.40.3951
Slightly volatile
Short Term Coverage Ratios0.460.770.2993
Slightly volatile
Operating Cycle119115172
Slightly volatile
Days Of Payables Outstanding34.1135.93.5 K
Slightly volatile
Long Term Debt To Capitalization0.210.220.5626
Very volatile
Total Debt To Capitalization0.860.510.6415
Slightly volatile
Quick Ratio1.581.667.9167
Slightly volatile
Net Income Per E B T0.71.130.945
Pretty Stable
Cash Ratio0.790.836.8157
Slightly volatile
Days Of Inventory Outstanding52.9156.8683.5457
Slightly volatile
Days Of Sales Outstanding65.9858.388.0046
Slightly volatile
Debt Ratio0.520.40.3951
Slightly volatile
Gross Profit Margin0.870.830.7998
Very volatile

Puma Biotechnology Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap162.1 M170.6 M1.2 B
Slightly volatile
Enterprise Value167.4 M176.2 M1.1 B
Slightly volatile

Puma Fundamental Market Drivers

Forward Price Earnings3.459
Cash And Short Term Investments101 M

Puma Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Puma Biotechnology Financial Statements

Investors use fundamental indicators, such as Puma Biotechnology's revenue or net income, to determine how well the company is positioned to perform in the future. Although Puma Biotechnology's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue5.3 M5 M
Total Revenue265 M135.4 M
Cost Of Revenue74.1 M77.8 M
Stock Based Compensation To Revenue 0.04  0.04 
Sales General And Administrative To Revenue 0.40  0.38 
Research And Ddevelopement To Revenue 0.27  0.26 
Revenue Per Share 4.26  3.66 
Ebit Per Revenue 0.13  0.15 

Currently Active Assets on Macroaxis

FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
CSANCosan SA ADR
RKTRocket Companies
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:
How To Invest In Puma
Details
Is Puma Stock a good investment?
Details
What is Puma Biotechnology's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Puma Biotechnology Correlation against competitors.
For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is there potential for Biotechnology market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.58)
Earnings Share
0.74
Revenue Per Share
4.267
Quarterly Revenue Growth
(0.32)
Return On Assets
0.099
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY